Carfentanil

bradycardia, heart block, heart failure, coronary artery disease

Carfentanil produces dose-dependent bradycardia even at PET tracer doses (>100 ng/kg IV) in anesthetized rats. Cardiac arrest is a common cause of death in overdose modeling. Pre-existing cardiovascular disease, particularly conduction abnormalities, would compound these cardiotoxic effects.

COPD, sleep apnea, pneumonia, acute asthma, restrictive lung disease

Any pre-existing condition that reduces respiratory reserve would be expected to lower the already vanishingly small lethal threshold. Respiratory depression is the dominant mechanism of death from carfentanil exposure, and the margin between any pharmacologically active dose and a lethal dose is effectively zero in healthy individuals — any respiratory compromise eliminates whatever margin might exist.

cirrhosis, hepatitis, severe hepatic insufficiency

Hepatic impairment would reduce CYP3A4/3A5-mediated clearance of carfentanil, potentially prolonging exposure and increasing toxicity. The active metabolite M2/M0 (EC₅₀ = 0.0051 nM, comparable to parent) may also accumulate unpredictably with altered hepatic function.

itraconazole, ketoconazole, clarithromycin, erythromycin, ritonavir, diltiazem, verapamil, grapefruit juice

CYP3A4/3A5 inhibitors would be expected to increase carfentanil plasma concentrations and toxicity by reducing metabolic clearance. In vitro CYP phenotyping (Kong & Walz 2021) identifies CYP3A5 as the primary enzyme and CYP3A4 as secondary. No clinical drug interaction studies exist; all predictions are from in vitro microsomal data.

pregnancy, breastfeeding

All µ-opioid agonists cross the placenta and can produce neonatal opioid withdrawal syndrome. Carfentanil's extreme potency at sub-microgram doses amplifies fetal risk beyond that of standard opioids. No carfentanil-specific pregnancy data exist.

benzodiazepines, barbiturates, alcohol, other opioids, z-drugs, gabapentinoids, sedating antihistamines

Co-administration with any CNS depressant produces synergistic respiratory depression, the primary mechanism of death in carfentanil overdose. Forensic case series from Ontario (Solbeck et al. 2021, n=160 deaths) confirm that the majority of carfentanil-associated fatalities involve polydrug toxicity. Given that carfentanil typically enters the drug supply as an adulterant in heroin, co-exposure with other depressants is the norm rather than the exception.

no naloxone available, no nalmefene available, no medical supervision

Carfentanil overdose reversal requires antagonist doses far exceeding standard community naloxone kits. Standard 2–4 mg intranasal naloxone may be inadequate due to carfentanil's slow receptor dissociation and antagonist-resistant µOR conformations. Any exposure context without immediate access to naloxone (preferably high-dose or repeated), nalmefene, or medical supervision is contraindicated.